Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Serina Therapeutics ( (SER) ) just unveiled an update.
On November 7, 2025, Serina Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders. During the meeting, Steve Ledger and Karen J. Wilson were elected as directors to serve until the 2028 Annual Meeting. Additionally, the appointment of Frazier & Deeter, LLC as the company’s independent auditors for the 2025 fiscal year was ratified. The issuance of common stock related to the Convertible Note and Warrants was also approved.
The most recent analyst rating on (SER) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Underperform.
The overall stock score for Serina Therapeutics is primarily driven by its poor financial performance, which is the most significant factor. The technical analysis also indicates bearish trends, further contributing to the low score. The valuation metrics reflect high risk due to negative profitability. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
Average Trading Volume: 127,424
Technical Sentiment Signal: Sell
Current Market Cap: $40.9M
For detailed information about SER stock, go to TipRanks’ Stock Analysis page.